Thursday, December 14, 2017 10:15 PM ET
Insider Makes Significant Stock buy in Fennec Pharmaceuticals (FENC) Shares Breaks neutral Trend of Last 90 Days
An insider — Spa Essetifin, 10% Owner — acquired 294,115 shares of Fennec Pharmaceuticals having a market value of approximately $2,499,978 today, as revealed in a form 4 document filed with the SEC. This is the first insider buy/sell trade in the past 90 days.
The level of buy-sell trading at Fennec Pharmaceuticals is near the 278 member peer company average. The Bio Therapeutic Drugs peer group saw 322 buy/sell trades during this period for an average of 1.2 transactions per company. However, the number of shares per buy/sell trade transacted by Fennec Pharmaceuticals insiders is higher. Within the peer group there were 37,673,537 shares purchased and 40,483,383 shares sold with company insiders selling 8,726 shares on average.
To bring into focus significant insider buying and selling activity, all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers has been eliminated in data sourced to create and write this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2017 UpTick Data Technologies. All rights reserved.